Concerns about PhII Parkinson gene therapy sends Neurologix into bankruptcy
This article was originally published in Scrip
Neurologix Inc. filed for voluntary Chapter 7 bankruptcy protection in US Bankruptcy Court for the District of Delaware on 16 March to liquidate assets after it spent the past year looking for financing or a partner to advance its Parkinson's disease gene therapy into Phase III clinical trials.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.